Human immunodeficiency virus infection and non-small cell lung cancer: Survival and toxicity of antineoplastic chemotherapy in a cohort study

Journal of Thoracic Oncology

Volumn 6, Issue 6, 2011, Pages 1022-1029

  Makinson, Alain ^a,b   Tenon, Jean Charles ^a   Eymard Duvernay, Sabrina ^b   Pujol, Jean Louis ^c   Allavena, Clotilde ^d   Cuzin, Lise ^e   Poizot Martin, Isabelle ^f   De La Tribonnière, Xavier ^g   Cabié, André ^h   Pugliese, Pascal ⁱ   Reynes, Jacques ^a,b   Le Moing, Vincent ^a,b  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e CHU PURPAN   (France)

^f HÔPITAL SAINTE MARGUERITE   (France)

^g Infectious Diseases Department   (France)

^h CHU Fort de France   (France)

ⁱ UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

Antiretroviral therapy; CD4 lymphocytes; Chemotherapy; HAART; HIV; Interaction; Lung cancer; NSCLC; Toxicity

Indexed keywords

ABACAVIR; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DIDANOSINE; DOCETAXEL; EFAVIRENZ; EMTRICITABINE; ETOPOSIDE; FOSAMPRENAVIR; GEFITINIB; GEMCITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NAVELBINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEMETREXED; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SMOKING; SURVIVAL RATE; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 79958095514     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318217b6e0     Document Type: Article

References (55)

1. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-1654. (Pubitemid 44162407)
2. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67. (Pubitemid 47017468)
3. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 2009; 48:633-639.
4. Grulich AE, Li Y, McDonald A, et al. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002;16:1155-1161. (Pubitemid 34533854)
5. Chaturvedi AK, Pfeiffer RM, Chang L, et al. Elevated risk of lung cancer among people with AIDS. AIDS 2007;21:207-213. (Pubitemid 46036929)
6. Duval X, Baron G, Garelik D, et al. Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study. Antiviral Ther 2008;13:389-397. (Pubitemid 352016732)
7. Bedimo RJ, McGinnis KA, Dunlap M, et al. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 2009;52:203-208.
8. Sigel K, Wisnivesky J, Justice A, et al. HIV infection is an independent risk factor for lung cancer CROI 2010, February 16-19, 2010, abstract 30.
9. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009;10:1152-1159.
10. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266.
11. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-1531.
12. Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
13. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
14. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
15. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304:321-333.
16. Makinson A, Martelli N, Peyriere H, et al. Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. Eur J Haematol 2007; 78:358-360. (Pubitemid 46365089)
17. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002;100:1984-1988. (Pubitemid 35001227)
18. Martin P, Leonard JP, Coleman M, et al. Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. Clin Lymphoma Myeloma 2009;9:247-249.
19. Cingolani A, Torti L, Pinnetti C, et al. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. AIDS 2010;24:2408-2412.
20. Kotb R, Vincent I, Dulioust A, et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol 2006;76:269-271.
21. Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004;104:2943-2946. (Pubitemid 39434985)
22. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001;91:155-163. (Pubitemid 32052626)
23. Pugliese P, Cuzin L, Cabie A, et al. A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med 2009;10:504-511.
24. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705. (Pubitemid 47357521)
25. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714. (Pubitemid 47357522)
26. Lavole A, Chouaid C, Baudrin L, et al. Effect of highly active antiret-roviral therapy on survival of HIV infected patients with non-small-cell lung cancer. Lung Cancer 2009;65:345-350.
27. Spano JP, Massiani MA, Bentata M, et al. Lung cancer in patients with HIV Infection and review of the literature. Med Oncol 2004;21:109-115. (Pubitemid 39108000)
28. Brock MV, Hooker CM, Engels EA, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 2006;43: 47-55. (Pubitemid 44306487)
29. Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285:1736-1745. (Pubitemid 32259908)
30. Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26, 957 patients with NSCLC. J Thorac Oncol 2010;5:620-630.
31. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009;114:1306-1313.
32. Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001;112:909-915. (Pubitemid 32322915)
33. Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival - results of the German Multicenter Trial. Cancer 2006;106:1560-1568.
34. Evison J, Jost J, Ledergerber B, et al. HIV-associated non-Hodgkin's lymphoma: highly active antiretroviral therapy improves remission rate of chemotherapy. AIDS 1999;13:732-734. (Pubitemid 29286712)
35. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483-1491. (Pubitemid 32744595)
36. Hoffmann C, Wolf E, Fatkenheuer G, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003;17:1521-1529. (Pubitemid 36900553)
37. Hentrich M, Maretta L, Chow KU, et al. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol 2006;17:914-919. (Pubitemid 43778980)
38. Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol 2004;125: 455-462. (Pubitemid 38916190)
39. Bolonaki I, Kotsakis A, Papadimitraki E, et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007;25: 2727-2734. (Pubitemid 47123180)
40. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625.
41. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
42. Rahman A, Korzekwa KR, Grogan J, et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994;54:5543-5546.
43. Harris JW, Katki A, Anderson LW, et al. Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol. J Med Chem 1994;37:706-709. (Pubitemid 24102192)
44. Li J, Zhao M, He P, et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13:3731-3737. (Pubitemid 46955138)
45. Gazzard BG. British HIV. Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
46. Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 2002;46:3907-3916. (Pubitemid 35403268)
47. Drewe J, Gutmann H, Fricker G, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999;57:1147-1152. (Pubitemid 29171690)
48. Deng L, Tatebe S, Lin-Lee YC, et al. MDR and MRP gene families as cellular determinant factors for resistance to clinical anticancer agents. Cancer Treat Res 2002;112:49-66.
49. Bundow D, Aboulafia DM. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma. Am J Clin Oncol 2004;27:81-84. (Pubitemid 38176296)
50. Schwartz JD, Howard W, Scadden DT. Potential interaction of antiret-roviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma. AIDS 1999;13:283-284. (Pubitemid 29050419)
51. Nannan Panday VR, Hoetelmans RM, van Heeswijk RP, et al. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma-drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Cancer Chemother Pharmacol 1999;43:516-519. (Pubitemid 29187592)
52. Ribera JM, Oriol A, Morgades M, et al. Safety and efficacy of cyclo-phosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 2008;140:411-419.
53. Moyle G, Sawyer W, Law M, et al. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther 2004;26:92-97. (Pubitemid 38241526)
54. Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 2008;9:336-388. (Pubitemid 352015641)
55. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)